UCB recently announced that the US Food and Drug Administration (FDA) has approved a label extension for the company's anti-epileptic drug (AED) Vimpat (lacosamide) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients aged ≥4 years. UCB is headquartered in Atlanta, GA, and Brussels, Belgium.
Indications: This new approval provides clinicians with the option to prescribe Vimpat to their pediatric patients either as an oral solution or a convenient tablet, allowing for flexible administration options, an important consideration when treating children.
Dosage/administration: For pediatric patients from 4 years to <17 years, the recommended dosage is based on body weight and is administered orally twice daily. Increased dosage is based on clinical response and tolerability, and no more frequently than once per week is recommended.
Adverse reactions: Adverse reactions in pediatric patients are similar those of adult patients: diplopia, headache, dizziness, and nausea.
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients. [news release]. Atlanta, GA, and Brussels, Belgium: UCB. November 6, 2017. https://www.prnewswire.com/news-releases/ucbs-vimpat-lacosamide-now-approved-by-fda-to-treat-partial-onset-seizures-in-pediatric-epilepsy-patients-300549924.html. Accessed November 9, 2017.
This Week's Must Reads
Coexisting Dementia Rising Among Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Mar 14; Sherzai, et al
Excessive Daytime Sleepiness and β-Amyloid Buildup, JAMA Neurology; ePub 2018 Mar 12; Carvalho, et al
Cognitive Impairment and ICAS in General Population, Neurology; ePub 2018 Mar 9; Suri, Zhou, et al
FDA Approves Apadaz for Acute Pain Relief, KemPharm, Inc. news release; 2018 Feb 23
FDA Expands Treatment Time for Clot Retrieval Device, FDA news release; 2018 Feb 15
Must Reads in Epilepsy & Seizures
Incidence of Periictal Apnea in Epileptic Seizures, Epilepsia; ePub 2018 Jan 16; Lacuey, Zonjy, et al
Epilepsy Seizure Rate and Education Level Linked, Epilepsy Behav; ePub 2017 Dec 24; Kumar, et al
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6
Psychogenic, Non-Epileptic Seizure Screening Aids, Epilepsia; ePub 2017 Sep 12; Kerr, Janio, et al
FDA Approves Antiepileptic Drug for Age 4 and Older, Sunovion news release; 2017 Sep 14